Insulin-like growth factor binding protein-3 mediates interleukin-24-induced apoptosis through inhibition of the mTOR pathway in prostate cancer

Du,Yuefeng; Long,Qingzhi; Shi,Ying; Liu,Xiaogang; Li,Xudong; Zeng,Jin; Gong,Yongguang; Li,Lei; Wang,Xinyang; He,Dalin

doi:10.3892/or.2015.4201

Insulin-like growth factor binding protein-3 mediates interleukin-24-induced apoptosis through inhibition of the mTOR pathway in prostate cancer

Authors:
- Yuefeng Du
- Qingzhi Long
- Ying Shi
- Xiaogang Liu
- Xudong Li
- Jin Zeng
- Yongguang Gong
- Lei Li
- Xinyang Wang
- Dalin He
View Affiliations

Affiliations: Department of Urology, First Affiliated Hospital of Medical School, Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China, Department of Urology, Tongji Medical College Union Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, P.R. China, School of Life Science and Technology, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China
Published online on: August 13, 2015 https://doi.org/10.3892/or.2015.4201
Pages: 2273-2281
Copyright: © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

IGF-binding protein-3 (IGFBP-3) has been shown to induce apoptosis in an insulin-like growth factor (IGF)‑independent manner in various cell systems, however, the underlying molecular mechanisms remain unknown. In the present study, we showed that IGFBP-3 significantly enhanced interleukin-24 (IL-24)-induced cell death in prostate cancer (PC) cell lines in vitro. Both the addition of IGFBP-3 to cell medium or the enforced expression of IGFBP-3 in the PC cell line inhibited activation of mammalian target of rapamycin (mTOR). Downregulation of mTOR/S6K reduced Mcl-1 protein expression and consequently promoted sensitization to IL-24 treatment. Overexpression of Mcl-1 reduced the level of cleaved poly(ADP-ribose) polymerase (PARP) induced by IL-24 and IGFBP-3, suggesting that the IL-24-induced apoptosis is realized by way of Mcl-1. We then showed that the combination of IL-24 and IGFBP-3 significantly suppressed PC tumor growth in vivo. We propose that the IGFBP-3 and IL-24 non-toxic mTOR inhibitors can be used as an adjuvant in the treatment of PC.

View Figures

View References

1	Gill ZP, Perks CM, Newcomb PV and Holly JM: Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem. 272:25602–25607. 1997. View Article : Google Scholar : PubMed/NCBI
2	Nakamura M, Takakura M, Fujii R, Maida Y, Bono Y, Mizumoto Y, Zhang X, Kiyono T and Kyo S: The PRB-dependent FOXO1/IGFBP-1 axis is essential for progestin to inhibit endometrial epithelial growth. Cancer Lett. 336:68–75. 2013. View Article : Google Scholar : PubMed/NCBI
3	Hanafusa T, Shinji T, Shiraha H, Nouso K, Iwasaki Y, Yumoto E, Ono T and Koide N: Functional promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor specific methylation. BMC Cancer. 5:92005. View Article : Google Scholar : PubMed/NCBI
4	Baxter RC, Butt AJ, Schedlich LJ and Martin JL: Antiproliferative and pro-apoptotic activities of insulin-like growth factor-binding protein-3. Growth Horm IGF Res. 10(10 Suppl A): S10–S11. 2000. View Article : Google Scholar : PubMed/NCBI
5	Ho L, Stojanovski A, Whetstone H, Wei QX, Mau E, Wunder JS and Alman B: Gli2 and p53 cooperate to regulate IGFBP-3-mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. Cancer Cell. 16:126–136. 2009. View Article : Google Scholar : PubMed/NCBI
6	Butt AJ and Williams AC: IGFBP-3 and apoptosis - a license to kill? Apoptosis. 6:199–205. 2001. View Article : Google Scholar : PubMed/NCBI
7	Williams AC, Collard TJ, Perks CM, Newcomb P, Moorghen M, Holly JM and Paraskeva C: Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res. 60:22–27. 2000.PubMed/NCBI
8	Hollowood AD, Lai T, Perks CM, Newcomb PV, Alderson D and Holly JM: IGFBP-3 prolongs the p53 response and enhances apoptosis following UV irradiation. Int J Cancer. 88:336–341. 2000. View Article : Google Scholar : PubMed/NCBI
9	Collard TJ, Guy M, Butt AJ, Perks CM, Holly JM, Paraskeva C and Williams AC: Transcriptional upregulation of the insulin-like growth factor binding protein IGFBP-3 by sodium butyrate increases IGF-independent apoptosis in human colonic adenoma-derived epithelial cells. Carcinogenesis. 24:393–401. 2003. View Article : Google Scholar : PubMed/NCBI
10	Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka M, Su Z, Lebedeva IV, Kang D, Jiang H, Lin JJ, Alexandre D, et al: Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene. 20:7051–7063. 2001. View Article : Google Scholar : PubMed/NCBI
11	Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S and Grimm EA: Loss of MDA-7 expression with progression of melanoma. J Clin Oncol. 20:1069–1074. 2002. View Article : Google Scholar : PubMed/NCBI
12	Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst J, Mumm JB, Leitner WW, Yang HY, Sahin AA, Hunt KK, Fuson KL, et al: MDA-7/IL-24 is a unique cytokine - tumor suppressor in the IL-10 family. Int Immunopharmacol. 4:649–667. 2004. View Article : Google Scholar : PubMed/NCBI
13	Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, Sarkar D, Wang XY, Gupta P, Emdad L, et al: The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther. 128:375–384. 2010. View Article : Google Scholar : PubMed/NCBI
14	Xu S, Oshima T, Imada T, Masuda M, Debnath B, Grande F, Garofalo A and Neamati N: Stabilization of MDA-7/IL-24 for colon cancer therapy. Cancer Lett. 335:421–430. 2013. View Article : Google Scholar : PubMed/NCBI
15	Gupta P, Emdad L, Lebedeva IV, Sarkar D, Dent P, Curiel DT, Settleman J and Fisher PB: Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva. J Cell Physiol. 215:827–836. 2008. View Article : Google Scholar : PubMed/NCBI
16	Deng WG, Kwon J, Ekmekcioglu S, Poindexter NJ and Grimm EA: IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways. Melanoma Res. 21:44–56. 2010. View Article : Google Scholar : PubMed/NCBI
17	Sauane M, Gopalkrishnan RV, Sarkar D, Su ZZ, Lebedeva IV, Dent P, Pestka S and Fisher PB: MDA-7/IL-24: Novel cancer growth suppressing and apoptosis inducing cytokine. Cytokine Growth Factor Rev. 14:35–51. 2003. View Article : Google Scholar
18	Mhashilkar AM, Schrock RD, Hindi M, Liao J, Sieger K, Kourouma F, Zou-Yang XH, Onishi E, Takh O, Vedvick TS, et al: Melanoma differentiation associated gene-7 (mda-7): A novel anti-tumor gene for cancer gene therapy. Mol Med. 7:271–282. 2001.PubMed/NCBI
19	Chada S, Mhashilkar AM, Liu Y, Nishikawa T, Bocangel D, Zheng M, Vorburger SA, Pataer A, Swisher SG, Ramesh R, et al: mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: Correlation with expression of bcl-2 family members. Cancer Gene Ther. 13:490–502. 2006. View Article : Google Scholar
20	Lebedeva IV, Sarkar D, Su ZZ, Kitada S, Dent P, Stein CA, Reed JC and Fisher PB: Bcl-2 and Bcl-x_L differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene. 22:8758–8773. 2003. View Article : Google Scholar : PubMed/NCBI
21	Ma XM and Blenis J: Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 10:307–318. 2009. View Article : Google Scholar : PubMed/NCBI
22	She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit DB and Rosen N: 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell. 18:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
23	Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 441:424–430. 2006. View Article : Google Scholar : PubMed/NCBI
24	Cusack JC Jr: Overcoming antiapoptotic responses to promote chemosensitivity in metastatic colorectal cancer to the liver. Ann Surg Oncol. 10:852–862. 2003. View Article : Google Scholar : PubMed/NCBI
25	Fabbri F, Brigliadori G, Carloni S, Ulivi P, Vannini I, Tesei A, Silvestrini R, Amadori D and Zoli W: Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. J Transl Med. 6:432008. View Article : Google Scholar : PubMed/NCBI
26	Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ, Trojahn U, Wendel HG, Charest A, Bronson RT, et al: mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA. 105:10853–10858. 2008. View Article : Google Scholar : PubMed/NCBI
27	Chan S: Targeting the mammalian target of rapamycin (mTOR): A new approach to treating cancer. Br J Cancer. 91:1420–1424. 2004. View Article : Google Scholar : PubMed/NCBI
28	Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D and Sonenberg N: mTOR signaling: Implications for cancer and anticancer therapy. Br J Cancer. 96(Suppl): R11–R15. 2007.PubMed/NCBI
29	Adams JM: Ways of dying: Multiple pathways to apoptosis. Genes Dev. 17:2481–2495. 2003. View Article : Google Scholar : PubMed/NCBI